JP2013525305A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525305A5 JP2013525305A5 JP2013505156A JP2013505156A JP2013525305A5 JP 2013525305 A5 JP2013525305 A5 JP 2013525305A5 JP 2013505156 A JP2013505156 A JP 2013505156A JP 2013505156 A JP2013505156 A JP 2013505156A JP 2013525305 A5 JP2013525305 A5 JP 2013525305A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- multimeric ligand
- subject
- region
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32512710P | 2010-04-16 | 2010-04-16 | |
| US61/325,127 | 2010-04-16 | ||
| US35176010P | 2010-06-04 | 2010-06-04 | |
| US61/351,760 | 2010-06-04 | ||
| US201161442582P | 2011-02-14 | 2011-02-14 | |
| US61/442,582 | 2011-02-14 | ||
| PCT/US2011/032572 WO2011130566A2 (en) | 2010-04-16 | 2011-04-14 | Method for treating solid tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016060361A Division JP2016117770A (ja) | 2010-04-16 | 2016-03-24 | 固形腫瘍を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013525305A JP2013525305A (ja) | 2013-06-20 |
| JP2013525305A5 true JP2013525305A5 (cg-RX-API-DMAC10.html) | 2014-05-01 |
| JP5975983B2 JP5975983B2 (ja) | 2016-08-23 |
Family
ID=44799326
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505156A Expired - Fee Related JP5975983B2 (ja) | 2010-04-16 | 2011-04-14 | 固形腫瘍を処置するための方法 |
| JP2016060361A Withdrawn JP2016117770A (ja) | 2010-04-16 | 2016-03-24 | 固形腫瘍を処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016060361A Withdrawn JP2016117770A (ja) | 2010-04-16 | 2016-03-24 | 固形腫瘍を処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20110287038A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2558109A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP5975983B2 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2011239569B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2795947A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2011130566A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2516320C (en) * | 2003-02-18 | 2015-05-26 | Kevin Slawin | Induced activation in dendritic cells |
| US8691210B2 (en) * | 2006-10-19 | 2014-04-08 | David M Spencer | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof |
| AU2009292996B2 (en) | 2008-09-22 | 2015-04-23 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters |
| AU2010310986A1 (en) | 2009-10-29 | 2012-06-14 | Aventis Pharma S.A. | Novel antitumoral use of cabazitaxel |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| US20130143237A1 (en) | 2011-11-29 | 2013-06-06 | Genentech, Inc. | Compositions and methods for prostate cancer analysis |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| CA2905352A1 (en) * | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| EP2970372B1 (en) | 2013-03-15 | 2020-09-30 | Celgene Corporation | Modified t lymphocytes |
| WO2014144731A2 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same |
| MX428954B (es) * | 2013-03-15 | 2025-11-13 | Univ Pennsylvania | Vacunación mejorada contra la hormona liberadora de la hormona de crecimiento (ghrh) humana. |
| EP3569253A1 (en) | 2013-06-05 | 2019-11-20 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| JP6496472B2 (ja) * | 2013-07-03 | 2019-04-03 | 三菱重工機械システム株式会社 | 車載器、及びスプーフィング検知方法 |
| EP3104866A4 (en) * | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| EP2940136A1 (en) * | 2014-04-30 | 2015-11-04 | QIAGEN GmbH | Method for isolating poly(A) nucleic acids |
| AU2015312117A1 (en) | 2014-09-02 | 2017-03-02 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides |
| WO2016071758A1 (en) | 2014-11-03 | 2016-05-12 | Leiden University Medical Center | T cell receptors directed against bob1 and uses thereof |
| EP3215521B1 (en) * | 2014-11-06 | 2025-10-08 | University of Maryland, Baltimore | Cd8 and t cell receptor variants and methods of using same in modulating immune cell responses |
| EP3234145B1 (en) * | 2014-12-15 | 2019-06-05 | Bellicum Pharmaceuticals, Inc. | Methods for controlled activation or elimination of therapeutic cells |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| US20190008897A1 (en) * | 2015-07-22 | 2019-01-10 | University Of Washington | Compositions and methods for producing pro-inflammatory macrophages |
| JP7032304B2 (ja) | 2015-07-28 | 2022-03-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | キメラ抗原受容体を発現する改変された単球／マクロファージおよびその使用 |
| CA3002685A1 (en) * | 2015-10-30 | 2017-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment of her2-expressing solid tumors |
| JP6904667B2 (ja) | 2016-06-14 | 2021-07-21 | 日本光電工業株式会社 | バイトブロック及びガスセンサキット |
| WO2018077385A1 (en) * | 2016-10-25 | 2018-05-03 | Biontech Rna Pharmaceuticals Gmbh | Dose determination for immunotherapeutic agents |
| EP3621988A1 (en) | 2017-05-09 | 2020-03-18 | Bellicum Pharmaceuticals, Inc. | Methods to augment or alter signal transduction |
| EP3675902A4 (en) | 2017-08-28 | 2021-06-23 | Board of Trustees of Michigan State University | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER AND INFECTION USING BACTERIOPHAGE AND THEIR MUTANTS |
| BR112020005938A2 (pt) | 2017-09-27 | 2020-11-17 | University Of Southern California | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso |
| AU2018378955A1 (en) | 2017-12-08 | 2020-06-18 | Bellicum Pharmaceuticals, Inc. | Methods for enhancing and maintaining CAR-T cell efficacy |
| WO2019126344A1 (en) | 2017-12-20 | 2019-06-27 | Bellicum Pharmaceuticals, Inc. | Multimeric piperidine derivatives |
| US20220000921A1 (en) * | 2018-11-20 | 2022-01-06 | Innovative Cellular Therapeutics Holdings, Ltd. | Modified Cell Expressing Therapeutic Agent and Uses thereof |
| US12702708B2 (en) | 2019-08-21 | 2026-08-11 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
| WO2021046243A2 (en) | 2019-09-03 | 2021-03-11 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| MX2022007107A (es) * | 2019-12-11 | 2022-11-14 | Myeloid Therapeutics Inc | Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas. |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| CA3162074A1 (en) * | 2020-01-10 | 2021-07-15 | Joseph HORVATINOVICH | Methods of treating tumors |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| EP4161536A4 (en) | 2020-06-04 | 2024-08-14 | Carisma Therapeutics Inc. | Novel constructs for chimeric antigen receptors |
| KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
| EP4240367A4 (en) | 2020-11-04 | 2024-10-16 | Myeloid Therapeutics, Inc. | MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| KR20240013094A (ko) | 2021-03-17 | 2024-01-30 | 마이얼로이드 테라퓨틱스, 인크. | 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법 |
| WO2022241029A1 (en) | 2021-05-11 | 2022-11-17 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050215472A1 (en) * | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| CA2516320C (en) * | 2003-02-18 | 2015-05-26 | Kevin Slawin | Induced activation in dendritic cells |
| JP2007511507A (ja) * | 2003-11-14 | 2007-05-10 | ジェンベク、インコーポレイティッド | 癌を処置するための治療レジメン |
| US8691210B2 (en) * | 2006-10-19 | 2014-04-08 | David M Spencer | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof |
| US8236318B2 (en) * | 2007-11-07 | 2012-08-07 | Celldex Therapeutics Inc. | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| AU2009221915A1 (en) * | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 12 binding proteins |
| WO2009151503A2 (en) * | 2008-04-10 | 2009-12-17 | University Of Florida Research Foundation, Inc. | Compositions and methods for the treatment of a neoplasia |
| AU2009292996B2 (en) * | 2008-09-22 | 2015-04-23 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters |
-
2011
- 2011-04-14 JP JP2013505156A patent/JP5975983B2/ja not_active Expired - Fee Related
- 2011-04-14 AU AU2011239569A patent/AU2011239569B2/en not_active Ceased
- 2011-04-14 EP EP11769619.5A patent/EP2558109A4/en not_active Withdrawn
- 2011-04-14 WO PCT/US2011/032572 patent/WO2011130566A2/en not_active Ceased
- 2011-04-14 CA CA2795947A patent/CA2795947A1/en not_active Abandoned
- 2011-04-14 US US13/087,329 patent/US20110287038A1/en not_active Abandoned
-
2013
- 2013-03-06 US US13/786,652 patent/US20140023647A1/en not_active Abandoned
-
2016
- 2016-03-24 JP JP2016060361A patent/JP2016117770A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brunell et al. | Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities | |
| CN115297868B (zh) | 用于编码核糖核酸的器官保护性表达和调节的组合物及方法 | |
| CN112055695A (zh) | 用于基因表达的纳米粒子和其用途 | |
| CN117721084A (zh) | 靶向多种抗原的复合嵌合抗原受体（cCAR）及其组成和使用方法 | |
| KR102741572B1 (ko) | 조직에서 코딩 리보핵산의 표적화된 전달, 발현 및 조절을 위한 조성물 및 방법 | |
| WO2017075465A1 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 | |
| US11788093B2 (en) | Chimeric antigen receptor t-cells expressing interleukin-8 receptor | |
| Wang et al. | Different evasion strategies in multiple myeloma | |
| Lee et al. | Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models | |
| JP2022546282A (ja) | Ｇｏｌｄ制御導入遺伝子による併用療法 | |
| Walters et al. | Modulating expression of inhibitory and stimulatory immune ‘checkpoints’ using nanoparticulate-assisted nucleic acid delivery | |
| KR20220092543A (ko) | 암의 치료를 위한 의약, 조합 의약, 의약 조성물, 면역 응답성 세포, 핵산 전달 비히클 및 제품 | |
| CN107427581A (zh) | T细胞群的改变方法 | |
| Snyder et al. | Good CARMA: Turning bad tumor‐resident myeloid cells good with chimeric antigen receptor macrophages | |
| Huang et al. | Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer | |
| Aljabali et al. | The dual promise of oncolytic viruses: selective targeting and therapeutic enhancement in cancer treatment | |
| Nicolaou et al. | Emerging insights into the immunosuppressive tumor microenvironment and its implications for glioblastoma immunotherapy | |
| US20240218019A1 (en) | Methods and compositions comprising mhc class i peptides | |
| Yuan et al. | CD8+ T Cells in Gastrointestinal Cancer: a Perspective on Targeting MicroRNA | |
| WO2024189109A1 (en) | Mutants of a ligand-dependent corepressor (lcor) and uses thereof | |
| Carreira et al. | Nanomedicines as multifunctional modulators of melanoma immune microenvironment | |
| Mokhtari et al. | The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. Cancers. 2021; 13: 3596 | |
| CN113929767A (zh) | 具有高亲和力的t细胞受体及其用途 | |
| EP4711380A1 (en) | Ligand-dependent corepressor, (lcor), mutants and fragments thereof, and uses for cancer therapy | |
| US20220372170A1 (en) | Macrophage CAR (MOTO-CAR) In Immunotherapy |